PD-1 inhibitor + SOX chemotherapy

PD-1 inhibitor + SOX chemotherapy refers to a combination immunotherapy and chemotherapy regimen primarily utilized in the treatment of locally advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. The regimen consists of a programmed cell death protein 1 (PD-1) blocking monoclonal antibody—most notably **tislelizumab** (also known as tirellizumab) in recent clinical trials—combined with the SOX chemotherapy doublet, which includes **S-1** (a multi-component oral fluoropyrimidine) and **oxaliplatin**. The mechanism of action involves the PD-1 inhibitor restoring T-cell mediated anti-tumor immunity by preventing the interaction between PD-1 and its ligands (PD-L1/PD-L2), while the SOX components provide cytotoxic effects: oxaliplatin induces DNA cross-linking and S-1 inhibits thymidylate synthase to disrupt DNA synthesis. This combination is frequently evaluated as a neoadjuvant therapy to increase major pathological response (mPR) rates and improve surgical outcomes in patients with resectable gastric cancers.

Other names

tislelizumab + S-1 + oxaliplatintislelizumab + SOXaPD-1 + SOX chemotherapyTirellizumab + SOX chemotherapy